Citadel Advisors
ONCY

Citadel Advisors’s Oncolytics Biotech ONCY Stock Holding History

Citadel Advisors’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8K Buy
19,813
+1,875
+10% +$1.74K ﹤0.01% 13416
2026
Q1 		$15.2K Buy
+17,938
New +$17.8K ﹤0.01% 12714
2025
Q4 		– Sell
-382,051
Closed -$535K – 13678
2025
Q3 		$535K Buy
+382,051
New +$428K ﹤0.01% 8963
2024
Q4 		– Sell
-79,249
Closed -$69K – 15127
2024
Q3 		$69K Sell
79,249
-57,836
-42% -$56.8K ﹤0.01% 11578
2024
Q2 		$136K Sell
137,085
-25,680
-16% -$28K ﹤0.01% 10490
2024
Q1 		$173K Buy
162,765
+48,880
+43% +$54.6K ﹤0.01% 10553
2023
Q4 		$154K Buy
+113,885
New +$178K ﹤0.01% 10343
2023
Q2 		– Sell
-87,858
Closed -$105K – 14972
2023
Q1 		$105K Buy
87,858
+50,587
+136% +$79.4K ﹤0.01% 11185
2022
Q4 		$60.8K Buy
+37,271
New +$56.6K ﹤0.01% 11899
2022
Q2 		– Sell
-11,639
Closed -$18K – 13744
2022
Q1 		$18K Sell
11,639
-83,696
-88% -$140K ﹤0.01% 13275
2021
Q4 		$133K Buy
95,335
+78,347
+461% +$145K ﹤0.01% 12415
2021
Q3 		$36K Sell
16,988
-12,401
-42% -$28.1K ﹤0.01% 13511
2021
Q2 		$81K Sell
29,389
-19,989
-40% -$61.2K ﹤0.01% 13070
2021
Q1 		$188K Buy
+49,378
New +$147K ﹤0.01% 11778
2020
Q4 		– Sell
-23,139
Closed -$39K – 11350
2020
Q3 		$39K Sell
23,139
-14,897
-39% -$27.3K ﹤0.01% 9681
2020
Q2 		$72K Buy
+38,036
New +$71.6K ﹤0.01% 9143
2020
Q1 		– Sell
-32,465
Closed -$154K – 9997
2019
Q4 		$154K Buy
32,465
+15,549
+92% +$17.6K ﹤0.01% 8348
2019
Q3 		$10K Buy
+16,916
New +$17.2K ﹤0.01% 9040
2019
Q2 		– Sell
-29,520
Closed -$54K – 9661
2019
Q1 		$54K Buy
+29,520
New +$59.8K ﹤0.01% 8791

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SI
Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Citadel Advisors's ONCY Position: Q2 2026 in Review

Citadel Advisors increased its Oncolytics Biotech (ONCY) stake by 10% in Q2 2026, buying an estimated $1.74K and bringing the position to 19,813 shares worth $18.8K. The position accounts for ﹤0.01% of the portfolio, ranked #13416.

Citadel Advisors first reported a position in ONCY in Q1 2019 and has held it in 19 quarters since. The position peaked at $535K in Q3 2025. 75 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • Citadel Advisors held 19,813 shares of Oncolytics Biotech worth $18.8K as of Q2 2026.
  • Citadel Advisors bought 1,875 Oncolytics Biotech shares in Q2 2026, an estimated $1.74K.
  • Oncolytics Biotech made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13416 holding.
  • Citadel Advisors first reported a position in Oncolytics Biotech in Q1 2019 and has held it in 19 quarters since.
  • Citadel Advisors's Oncolytics Biotech position peaked at $535K in Q3 2025.
  • 75 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.